After a technology spin-out from Nitto Denko Corporation (Japan’s leading diversified materials manufacturer), PassPort Technologies was established in San Diego, California, to continue R&D efforts towards the commercialization of improved pharmaceutical products using its patent-protected transdermal drug delivery platform (PassPort® System). The result is a unique drug repositioning opportunity for companies who already offer approved therapeutics, as well as those developing new NCE candidates that could benefit from alternative/improved routes of administration. The novel PassPort® System combines microporation technology to painlessly create micropores on the skin surface and patch formulation technology that controls drug absorption through the micropores. By using the PassPort® System, it is now possible for transdermal needle-free administration of drugs that have previously been limited to injections or infusions. This platform is not only applicable to low molecular weight drugs but also for other modalities such as peptides, oligonucleotides and proteins.